Successfully reported this slideshow.

Empower oncologists. Revolutionize biopharma.

3

Share

Loading in …3
×
1 of 12
1 of 12

Empower oncologists. Revolutionize biopharma.

3

Share

Download to read offline

Description

Read about rapid innovation in oncology & the pressures healthcare ecosystems & processes are under.

Transcript

  1. 1. Empower oncologists. Revolutionize biopharma. Accenture Life Sciences New Science. Transformative patient outcomes.
  2. 2. The convergence of science and technology make treatment decisions more complex and oncologists urgently need support to make the best treatment decision for patients. In this rapidly changing landscape, biopharma companies can differentiate themselves from competitors by meeting the individual needs of oncologists in new, tailored ways that improve patient outcomes. 2 Copyright © 2021 Accenture. All rights reserved. Science & technology are converging
  3. 3. 3 Copyright © 2021 Accenture. All rights reserved. The survey was split evenly between oncologists in academic medical centers and community practices. Our results identified the support and services they need to focus more on patients. Accenture surveyed 120 oncologists across the US and Germany
  4. 4. How can biopharmaceutical companies empower oncologists in this complex environment? 4 Copyright © 2021 Accenture. All rights reserved.
  5. 5. 5 Copyright © 2021 Accenture. All rights reserved.
  6. 6. Most services require only a general medical background. However, there are a handful of advanced services that require experienced oncologists or specialists. Medical background is sufficient An understanding of oncology would be ideal but is not mandatory for many services Experienced oncologist desired Peer-to-peer discussions are desired for some advanced services Additional specialization required This includes discussions on genomic sequencing, biomarkers, genomic or biomarker results, and molecular pathways related to specific indications 6 Copyright © 2021 Accenture. All rights reserved. Who should deliver the support?
  7. 7. 43 percent of all oncologists believe that real world data (RWD) and clinical trial data (CTD) will be equally important sources of clinical decision support data going forward. RWD is being seen as a top 5 priority service of oncologists say they “will need more discussion” on RWD in the future of oncologists want pharma representatives to discuss RWD with them 65% 51% 7 Copyright © 2021 Accenture. All rights reserved. Overall Community practitioners Academic medical centers 43% 28% 57% Oncologists that believe RWD and CTD will equally inform treatment decisions in the next 10 years Focus on two types of data
  8. 8. Technology is expected to become the key force shaping treatment decisions going forward Discussions with biopharma representatives are expected to become less important Factors that will shape treatment decisions going forward 8 Copyright © 2021 Accenture. All rights reserved. Technology’s new role in clinical decisions
  9. 9. Human interaction is vital as face-to-face and virtual ranked highest Newer channels—smartphone apps and social media— ranked equal or preferred over meetings and e-mail Preferred interaction channels for oncologists 9 Copyright © 2021 Accenture. All rights reserved. Physicians preferred information access channels
  10. 10. The services critical to the future of oncology can be grouped into these imperatives. Patient specific discussions Strengthening the focus on medical capabilities Getting the basics right Recognizing the different needs of academic medical centers and community practice oncologists 01 04 Real-world data capabilities Training field forces and non-customer-facing employees with deep RWD expertise 02 Precision oncology support Broadening services for greater access to peers and experts 03 10 Copyright © 2021 Accenture. All rights reserved. Four imperatives for biopharma
  11. 11. Innovative and excellent oncologist interaction will separate leaders from followers, ultimately enabling differentiated outcomes for patients and health care ecosystems. Here are three things biopharma companies should do to set themselves apart: Act now to be future ready Co-create new peer network ecosystems Build a future-ready customer facing team Leverage new technology to drive insights 11 Copyright © 2021 Accenture. All rights reserved.
  12. 12. 12 Copyright © 2021 Accenture. All rights reserved. For more information Access the full report for more information here. To learn how Accenture is helping clients manage and drive exceptional growth in precision medicine, visit here. Authors Dr. Boris Bogdan Managing Director, Lead—Global Precision Oncology and PHC, Life Sciences boris.bogdan@accenture.com Dr.AndréT.Dahinden Managing Director, Co-Lead—Global PrecisionOncology and PHC, Life Sciences andre.dahinden@accenture.com Dr.AbhishekKurne Principal Director, Life Sciences, Accenture abhishek.kurne@accenture.com Dr. Sandra Dietschy-Kuenzle Senior Principal, Life Sciences, Accenture s.dietschy-kuenzle@accenture.com

Description

Read about rapid innovation in oncology & the pressures healthcare ecosystems & processes are under.

Transcript

  1. 1. Empower oncologists. Revolutionize biopharma. Accenture Life Sciences New Science. Transformative patient outcomes.
  2. 2. The convergence of science and technology make treatment decisions more complex and oncologists urgently need support to make the best treatment decision for patients. In this rapidly changing landscape, biopharma companies can differentiate themselves from competitors by meeting the individual needs of oncologists in new, tailored ways that improve patient outcomes. 2 Copyright © 2021 Accenture. All rights reserved. Science & technology are converging
  3. 3. 3 Copyright © 2021 Accenture. All rights reserved. The survey was split evenly between oncologists in academic medical centers and community practices. Our results identified the support and services they need to focus more on patients. Accenture surveyed 120 oncologists across the US and Germany
  4. 4. How can biopharmaceutical companies empower oncologists in this complex environment? 4 Copyright © 2021 Accenture. All rights reserved.
  5. 5. 5 Copyright © 2021 Accenture. All rights reserved.
  6. 6. Most services require only a general medical background. However, there are a handful of advanced services that require experienced oncologists or specialists. Medical background is sufficient An understanding of oncology would be ideal but is not mandatory for many services Experienced oncologist desired Peer-to-peer discussions are desired for some advanced services Additional specialization required This includes discussions on genomic sequencing, biomarkers, genomic or biomarker results, and molecular pathways related to specific indications 6 Copyright © 2021 Accenture. All rights reserved. Who should deliver the support?
  7. 7. 43 percent of all oncologists believe that real world data (RWD) and clinical trial data (CTD) will be equally important sources of clinical decision support data going forward. RWD is being seen as a top 5 priority service of oncologists say they “will need more discussion” on RWD in the future of oncologists want pharma representatives to discuss RWD with them 65% 51% 7 Copyright © 2021 Accenture. All rights reserved. Overall Community practitioners Academic medical centers 43% 28% 57% Oncologists that believe RWD and CTD will equally inform treatment decisions in the next 10 years Focus on two types of data
  8. 8. Technology is expected to become the key force shaping treatment decisions going forward Discussions with biopharma representatives are expected to become less important Factors that will shape treatment decisions going forward 8 Copyright © 2021 Accenture. All rights reserved. Technology’s new role in clinical decisions
  9. 9. Human interaction is vital as face-to-face and virtual ranked highest Newer channels—smartphone apps and social media— ranked equal or preferred over meetings and e-mail Preferred interaction channels for oncologists 9 Copyright © 2021 Accenture. All rights reserved. Physicians preferred information access channels
  10. 10. The services critical to the future of oncology can be grouped into these imperatives. Patient specific discussions Strengthening the focus on medical capabilities Getting the basics right Recognizing the different needs of academic medical centers and community practice oncologists 01 04 Real-world data capabilities Training field forces and non-customer-facing employees with deep RWD expertise 02 Precision oncology support Broadening services for greater access to peers and experts 03 10 Copyright © 2021 Accenture. All rights reserved. Four imperatives for biopharma
  11. 11. Innovative and excellent oncologist interaction will separate leaders from followers, ultimately enabling differentiated outcomes for patients and health care ecosystems. Here are three things biopharma companies should do to set themselves apart: Act now to be future ready Co-create new peer network ecosystems Build a future-ready customer facing team Leverage new technology to drive insights 11 Copyright © 2021 Accenture. All rights reserved.
  12. 12. 12 Copyright © 2021 Accenture. All rights reserved. For more information Access the full report for more information here. To learn how Accenture is helping clients manage and drive exceptional growth in precision medicine, visit here. Authors Dr. Boris Bogdan Managing Director, Lead—Global Precision Oncology and PHC, Life Sciences boris.bogdan@accenture.com Dr.AndréT.Dahinden Managing Director, Co-Lead—Global PrecisionOncology and PHC, Life Sciences andre.dahinden@accenture.com Dr.AbhishekKurne Principal Director, Life Sciences, Accenture abhishek.kurne@accenture.com Dr. Sandra Dietschy-Kuenzle Senior Principal, Life Sciences, Accenture s.dietschy-kuenzle@accenture.com

More Related Content

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

×